Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides potassium ions for maintenance of electrolyte balance and normal cellular function. Sodium chloride provides sodium and chloride ions to maintain extracellular fluid volume and osmolarity.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Fluid and electrolyte replacement in patients with hypokalemia and hyponatremia,Maintenance of electrolyte balance during intravenous fluid therapy
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion. The typical adult dose is 20-40 m Eq of potassium per day, administered as an infusion rate not exceeding 10 m Eq/hour or 0.5 m Eq/kg/hour. Concentration is 0.11% KCl (1.46 m Eq/L) provided in 0.9% Na Cl.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Not applicable; potassium is a physiologic ion with rapid equilibration; serum levels reflect total body stores and renal function; in anephric patients, half-life extends to 30-50 hours.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Not metabolized; excreted primarily by the kidneys as potassium and chloride ions
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Primarily renal (>90%) as potassium ions; negligible biliary/fecal elimination under normal conditions.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Minimal (<5%); does not significantly bind to plasma proteins.
Low protein binding; 0–11% bound, primarily to albumin.
Approximately 0.4 L/kg (total body water); potassium distributes primarily in the intracellular space (98%) with only 2% in extracellular fluid.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Oral: 100% (potassium chloride is fully absorbed); intravenous: 100% (direct administration).
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
GFR 30-60 m L/min: reduce potassium dose by 25-50% and monitor serum potassium. GFR <30 m L/min: avoid use unless severe hypokalemia and close monitoring; typically contraindicated for maintenance therapy.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific Child-Pugh based adjustments; however, patients with cirrhosis may have altered potassium homeostasis. Monitor serum potassium closely especially in ascites or diuretic use.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Weight-based: 0.2-0.5 m Eq/kg/dose as a continuous infusion, not to exceed 0.5 m Eq/kg/hour. Maximum daily dose: 2 m Eq/kg/day. Concentration should be diluted appropriately; typical product concentration is 0.11% (1.46 m Eq/L) in 0.9% Na Cl.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Initiate at lower end of adult dosing (20-30 m Eq/day) due to age-related renal impairment. Infusion rate not to exceed 5-10 m Eq/hour. Monitor renal function and serum potassium frequently.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Monitor serum electrolytes, renal function, and acid-base balance,Risk of hyperkalemia, especially in patients with renal impairment,Risk of fluid overload in patients with cardiac or renal disease,Solutions containing aluminum should not be used in patients with impaired renal function,Potassium administration may cause cardiac arrhythmias; use with caution in patients on digitalis
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperkalemia,Severe renal impairment or oliguria,Acute dehydration or heat cramps,Concurrent use of potassium-sparing diuretics,Acidosis,Hypersensitivity to any component
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, tomatoes, spinach, salt substitutes) while receiving this infusion, as it may increase the risk of hyperkalemia. No specific food restrictions otherwise, but maintain normal dietary patterns as tolerated.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Potassium chloride is an essential electrolyte. There is no evidence of teratogenicity at physiological doses. In overdose, fetal hyperkalemia and arrhythmias may occur. First trimester: No known teratogenic risk. Second and third trimesters: No known teratogenic risk; however, maternal hyperkalemia can cause fetal bradycardia and arrhythmias.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Potassium is a normal constituent of breast milk. Intravenous or oral potassium chloride administration does not significantly increase milk levels beyond normal physiological ranges. M/P ratio is approximately 1.0. Use is considered compatible with breastfeeding.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy does not significantly alter potassium pharmacokinetics. Dosing should be guided by serum potassium levels and clinical condition. No routine dose adjustment is required beyond standard adult dosing.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Potassium chloride 0.11% in sodium chloride 0.9% (KCl 0.11% / NS) provides approximately 14.9 m Eq/L of potassium and 154 m Eq/L of sodium. It is used for maintenance hydration and correction of mild hypokalemia. Infuse via central line only if concentration >0.2% KCl; this concentration is typically safe for peripheral administration. Monitor serum potassium and renal function; contraindicated in severe renal impairment, hyperkalemia, or adrenal insufficiency. Rate of administration should not exceed 10-20 m Eq/hour in non-emergency settings.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This intravenous solution contains potassium and salt to help maintain your body's fluid and electrolyte balance.,Tell your healthcare provider if you have kidney problems, heart disease, or are on any medications that affect potassium levels.,Report any signs of hyperkalemia such as muscle weakness, irregular heartbeat, or tingling sensations.,Do not stop or adjust the infusion rate yourself; it is given under close medical supervision.,Inform your doctor about all medications you take, especially potassium supplements, diuretics, or ACE inhibitors.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides potassium ions for maintenance of electrolyte balance and normal cellular function. Sodium chloride provides sodium and chloride ions to maintain extracellular fluid volume and osmolarity.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous infusion. The typical adult dose is 20-40 m Eq of potassium per day, administered as an infusion rate not exceeding 10 m Eq/hour or 0.5 m Eq/kg/hour. Concentration is 0.11% KCl (1.46 m Eq/L) provided in 0.9% Na Cl.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride is an essential electrolyte. There is no evidence of teratogenicity at physiological doses. In overdose, fetal hyperkalemia and arrhythmias may occur. First trim. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.